Physician profile
William Eng Lee
NPI 1639173693
$15,676.71
in general payments reported to CMS, 2019-2025
41 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,815 · 2020: $4,655 · 2021: $525 · 2022: $574 · 2023: $420 · 2024: $796 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $5,687.25 | 2019-2025 | Reblozyl |
| Genzyme Corporation | $2,488.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,143.64 | 2019-2024 | Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,061.05 | 2019-2025 | Augtyro, Reblozyl |
| Amgen INC. | $1,055.16 | 2019-2020 | |
| Genmab U.S., INC. | $894.91 | 2021-2025 | Epkinly, Tivdak |
| Glaxosmithkline, LLC. | $473.30 | 2020-2025 | Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $321.49 | 2019-2022 | |
| Eisai INC. | $297.29 | 2019-2020 | |
| Abbvie INC. | $241.97 | 2024-2025 | |
| Janssen Biotech, INC. | $224.14 | 2019-2025 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $181.24 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $177.62 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $161.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $106.18 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.